A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

计划入组 2 人 · 首次发布于 2021 年 8 月 23 日

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

计划入组 19 人 · 首次发布于 2012 年 12 月 7 日

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

计划入组 19 人 · 首次发布于 2017 年 7 月 2 日

Betibeglogene autotemcel(Zynteglo)

γ-globin gene therapy(CSL Behring LLC)

β-globin restored autologous hematopoietic stem cells (Hemogen Gene)

JIUYUAN GENE

Triple-Gene LLC

United States

MOMOTARO-GENE INC.

Japan

Lonza and Genetix Extend Manufacturing Partnership for ZYNTEGLO Gene Therapy Amid Rising Patient Demand

CRISPR-Based Casgevy Emerges as Preferred Gene Therapy for Beta-Thalassemia, Survey Shows

Kanglin Biotechnology Secures $20 Million to Advance KL003 Gene Therapy for Beta Thalassemia and Sickle Cell Disease